Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field

Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment

Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases 

The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed

Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease 

Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors

Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China

Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes

Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy

Positive results are reported from the FZOCUS-1 and ICON8B studies